Global Gastrointestinal Drugs Market Production, Growth Rate, and Comparison by Types 2020-2027 The Insight Partners provides details the “Gastrointestinal Drugs Market Forecast to 2027”. The main points in the market, market performance, market key growth factors, value chain analysis, SWOT analysis, and more. According to our new market research study on “Gastrointestinal Drugs Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Drug Class, Route of Administration, Application, and Distribution Channel,” the market is expected to reach US$ 71,300.28 million in 2027 from US$ 49,043.38 million in 2020. The market is estimated to grow at a CAGR of 4.9% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth. Request a sample copy of this report @ https://www.theinsightpartners.com/sample/TIPRE00014758/ Biologics are beneficial for patients with gastrointestinal disorders who are not responding to conventional treatment. For instance, infliximab, which is derived from monoclonal antibodies to tumor necrosis factor is another modifier of the immune system's actions. Infliximab is given as a series of infusions by vein. This drug can be given to treat moderate to severe Crohn’s disease that has not responded to other drugs, to treat people with fistulas, and to maintain response when the disease is difficult to control. Vedolizumab and natalizumab are drugs for people who have moderate to severe Crohn’s disease that have not responded to TNF inhibitors or other immunomodulating drugs. With the increasing number of biologics in pipeline, the segment is expected to grow at a rapid pace during the forecast period. For instance, Takeda Pharmaceutical Company Limited has five candidates in different phases for various GI indications. Geographically, the Gastrointestinal Drugs market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South and Central America (Brazil, Argentina, and the Rest of SCAM). The following manufacturers are covered: Sanofi,GlaxoSmithKline plc,Johnson and Johnson Services, Inc.,Bausch Health,AstraZeneca,Takeda Pharmaceutical Company Limited,AbbVie Inc.,Bayer AG,Celltrion Healthcare Co.,Ltd,LEXICON PHARMACEUTICALS, INC By Drug Class Acid Neutralizers Antidiarrheal and Laxatives Anti-Inflammatory Drugs Antiemetic and Antinauseants Biologics Others By Route of Administration Oral Parenteral By Application Inflammatory Ulcerative Colitis Crohn's Disease Irritable Bowel Syndrome Gastroenteritis Celiac Disease Others About The Insight Partners: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defence, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Sameer Joshi E-mail: sales@theinsightpartners.com Phone: +1-646-491-9876 #Gastrointestinal_Drugs, #Gastrointestinal_Drugs_Market, #Gastrointestinal_Drugs_Market_Analysis